Infectious Diseases
Combatting Infectious Diseases Through Advanced R&D Solutions
Infectious diseases have shaped the course of human history, toppling empires, redefining borders, and uniting scientists in the fight againstglobal pandemics. From ancient plagues to modern outbreaks, their impact is as far-reaching as it is devastating. Despite medical advancements,infectious diseases remain a leading cause of mortality worldwide,claiming over 13 million lives annually (WHO, 2023). But every great challenge inspires innovation. Today, the fight against infectious diseases demands cutting-edge research, robust models, and relentless determination to stay ahead of evolving threats. That’s where PharmaLegacy steps in.
Our mission is to empower antimicrobial drug discovery innovation through End-to-End solutions which cover in vitro activity screenings, IND-enabling studies and more.
PharmaLegacy’s infectious disease models are designed to accelerate your research, delivering actionable insights with precision and reliability.Whether you’re studying bacterial, viral, or fungal pathogens, our models provide robust, translatable data to help you make informed decisions faster.
When you choose PharmaLegacy, you’re partnering with a team that combines scientific expertise, cutting-edge technology, and a commitment to excellence. From preclinical evaluations to custom-tailored studies, we ensure your project is executed efficiently, on budget, and with the rigor needed to meet your milestones.
Available Animal Models
| Pathogens | Route | Readouts |
|---|---|---|
| A. baumannii (G-) | Deep-thigh, Lung, Ocular, Superficial, Systemic, Urinary, Vaginal | Body weight, Mortality, Bacteria Load, Pathology |
| E. coli (G-) | ||
| H. pylori (G-) | ||
| K. pneumoniae (G-) | ||
| P. aeruginosa (G-) | ||
| C. acnes (G+) | ||
| C. difficile (G+) | ||
| S. aureus (G+) | ||
| S. pneumoniae12 (G+) |
| Pathogens | Route | Readouts |
|---|---|---|
| A. flavus | Lung, Superficial, Systemic, Vaginal | Body weight, Mortality, Fungal Load, Pathology |
| A. fumigatus | ||
| A. niger | ||
| C. albicans | ||
| C. neoformans | ||
| M. sympodialis |
| Pathogens | Route | Readouts |
|---|---|---|
| Respiratory Syncytial Virus (A & B) | Lung, Ocular, Superficial, Systemic, Vaginal | Body weight, Mortality, Pathology, Viral load, Humoral Immunity, Cellular Immunity |
| Influenza Virus (A & B) | ||
| Herpes Simplex Virus (1 & 2) | ||
| Human Cytomegalovirus | ||
| Coxsackies Virus (A16 & B3) | ||
| Coronavirus (Non-SARS) | ||
| Hepatitis B Virus | ||
| VACV |
MODELS / SERVICES
The global burden of bacterial infections remains severe, driven by rising antimicrobial resistance (AMR) and complex polymicrobial infections. Severe bacterial infections (SBIs), such as those caused by Pseudomonas aeruginosa and Klebsiella pneumoniae, are linked to high mortality rates. Escherichia coli bloodstream infections (BSIs) are still particularly concerning. All of these necessitate early identification and the evaluation of promising therapeutic candidate drugs through predictive models,which is the specialty service PharmaLegacy provides.
| Pathogens | Route | Readouts |
|---|---|---|
| A. baumannii (G-) | Deep-thigh, Lung, Ocular, Superficial, Systemic, Urinary, Vaginal | Body weight, Mortality, Bacteria Load, Pathology |
| E. coli (G-) | ||
| H. pylori (G-) | ||
| K. pneumoniae (G-) | ||
| P. aeruginosa (G-) | ||
| C. acnes (G+) | ||
| C. difficile (G+) | ||
| S. aureus (G+) | ||
| S. pneumoniae12 (G+) |
Case study: Mouse Infection Model of Acinetobacter baumannii
- Hospital acquired pneumonia, Acinetobacter baumannii pneumonia
Case study: Mouse Infection Model of Escherichia coli
- Escherichia coli-associated pyomyositis
Case study: Mouse Infection Model of Klebsiella pneumoniae
- Carbapenem-resistant Klebsiella pneumoniae (CRKP) UTI
Case study: Mouse Infection Model of Pseudomonas aeruginosa
-
- Hospital acquired pneumonia, Pseudomonas aeruginosa pneumoni
Case study: Mouse Infection Model of Staphylococcus aureus
- Systemic infection, bacterial septicemia
Case study: Mouse Infection Model of Staphylococcus aureus
- Genital tract infection, bacterial vaginosis
Case study: Mouse Infection Model of Staphylococcus aureus
- Superficial bacterial skin infections, Impetigo, Folliculitis
Case study: Mouse Infection Model of Cutibacterium acnes
- Acne vulgaris, Furuncle/Carbuncle
The global landscape of viral infections remains dynamic, with influenza, SARS-CoV-2 variants, post pandemic RSV infections rebound, and emerging pathogens like novel bunyaviruses posing significant clinical challenges. Meanwhile, chronic HBV infections are still a critical global health burden despite vaccination success. As for HSV-1/2 infections, which affects 60-95% of adults globally, remain incurable with frequent reactivations linked to immunosuppression and stress.
To address these challenges, our platform offers comprehensive animal infection model services tailored for antiviral research.
| Pathogens | Route | Readouts |
|---|---|---|
| Respiratory Syncytial Virus (A & B) | Lung, Ocular, Superficial, Systemic, Vaginal | Body weight, Mortality, Pathology, Viral load, Humoral Immunity, Cellular Immunity |
| Influenza Virus (A & B) | ||
| Herpes Simplex Virus (1 & 2) | ||
| Human Cytomegalovirus | ||
| Coxsackies Virus (A16 & B3) | ||
| Coronavirus (Non-SARS) | ||
| Hepatitis B Virus | ||
| VACV |
Case study: Mouse Infection Model of Respiratory Syncytial Virus
- Respiratory Syncytial Virus Pneumonia, ALRTI
Case study: Mouse Infection Model of Influenza Virus
- Flu, Viral pneumonia, septicemia, ARDS
Case study: Mouse Infection Model of Herpes Simplex Virus 1
- Viral encephalitis
- Herpes simplex keratitis, HSK
Case study: Mouse Infection Model of Herpes Simplex Virus 2
- Genital Herpes, HSV Vulvitis
Case study: Mouse Infection Model of Coxsackies Virus B3
- Viral myocarditis
Case study: Mouse Model of Hepatitis B Virus
- AAVHBV model
- HDIHBV model
Case study: Mouse Model of Vaccinia Virus
- A replacement for monkeypox and smallpox
Invasive fungal infections (IFIs), driven by Candida spp., Aspergillus, and emerging pathogens like Lomentospora prolificans, pose escalating threats, particularly in immunocompromised populations. Mortalit rates exceed 40% in systemic candidiasis, exacerbated by delayed diagnostics and antifungal resistance.Environmental fungi also resurge due to climate shifts, while biofilm-associated infections hinder therapeutic efficacy.
The complexity of fungal pathogenesis, spanning host immune evasion, biofilm formation, and species-specific resistance, demands solid preclinical models that replicate clinical dynamics for candidate drugs screening.
| Pathogens | Route | Readouts |
|---|---|---|
| A. flavus | Lung, Superficial, Systemic, Vaginal | Body weight, Mortality, Fungal Load, Pathology |
| A. fumigatus | ||
| A. niger | ||
| C. albicans | ||
| C. neoformans | ||
| M. sympodialis |
Case study: Mouse Infection Model of Aspergillus flavus
- Invasive pulmonary aspergillosis
Case study: Mouse Infection Model of Aspergillus fumigatus
- Systemic aspergillosis
Case study: Mouse Infection Model of Candida albicans
- Vulvovaginal candidiasis
Case study: Mouse Infection Model of Cryptococcus neoformans
- Cryptococcal Meningitis
- Viral encephalitis model
- Bacterial meningitis model
- Fungal meningitis model
- Viral acute lung infection models
- Bacterial acute lung infection models
- Fungi acute lung infection models
- Viral pneumonia models
- Bacterial pneumonia models
- Fungal pneumonia models
- Bacterial/viral/fungal superinfection models
- Bacterial and fungal otitis model
- Bacterial conjunctivitis model
- Viral keratitis model
- HBV mouse model (AAV/HBV and HDI)
- Adenovirus-induced acute liver injury model
- Rotavirus-induced enteritis model
- C. difficile-induced enteritis
- H. pylori induced gastritis model
- Bacterial endocarditis model
-
Coxsackievirus B3-induced myocarditis model
- Herpes genitalis model
- Bacterial vaginitis model
- Fungal vulvoaginitis model
- Bacterial urinary track infection (UTI) model
- HSV-1-induced herpes labialis model
- Cutibacterium acnes-induced acne model
- Bacterial wound infection model
- Bacterial deep-thigh infection model
- Fungal superficial infection model
- Coxsackievirus A16 HFMD model
- Bacterial septicemia model
- Fungal systemic infection model
Committed to quality:
- 1,000+m2 AAALAC authorized ABSL2 animal facility
- 200+m2 NHC certified BSL2 labs
- More than 10 years of experience in the industry
- More than 20 successful IND cases
- FDA part 11 compliant
When fighting one of the leading causes of worldwide deaths, you need apartner with proven expertise and cutting-edge solutions. PharmaLegacy can be that partner. Get in touch now, and together, let’s build the breakthroughs that could stop the next pandemic in its tracks.
We’re ready when you are.
Tell us your pharmacology challenges.
